Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Pharmacogenetics > Exam 2 lectures 14 & 15 > Flashcards

Exam 2 lectures 14 & 15 Flashcards

(39 cards)

Start Studying
1
Q

targeted therapies are treatments that

A

target specific characteristics of diseased cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

targeted therapies are generally less

A

harmful to normal, healthy cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

targeted therapies can be various forms:

A

small molecules, RNA/DNA-based oligonucleotides, antibodies, & peptides/proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

key factors in the discovery & development of targeted therapy

A
  • new technology
  • new targets
  • target validation in early development phase
  • predictive models
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

molecular targeted drug may target at various levels:

A

molecular, cellular, tissue/organ, system, whole body, population

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

effects of targeted therapy can be

A

physiological
biochemical
functional

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

criteria for target validation

A
  • causal relation between target & disease
  • correlation with disease status
  • specificity
  • affinity
  • mode of action (onset)
  • regulation of effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

methods of target validation

A
  • molecular/ genetic/ genomic
  • biochemical/proteomic
  • physiological/functional
  • pharmacological/ tocicological
  • population-based
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

testing system in target validation

A
  • cell-free in vitro
  • cell
  • organ (in vitro & in vivo)
  • small animals
  • non-human primates
  • humans
  • computational biology/bioinformatics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

evaluation of target validation

A
  • qualitative (yes/no, withdrawal effect)
  • quantitative ( dose-effect& dose-response relationships)
  • biological effects vs. statistical signnificance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

dose-effect

A

individual level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

dose-response

A

group level

- most drugs are approved based on the population level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

interpretation of target validation

A
  • geno vs pheno
  • in vitro vs in vivo
  • animals vs humans
  • healthy subjects vs patients
  • other host factors (age,, sex, race)
  • other limitations (dose-range)
  • research tools vs drug class/entiiy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

biomarkers for selection of cancer therapy: EGFR

A
  • erlotinib (lung cancer)

- cetuximab (colon cancer)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

biomarkers for selection of cancer therapy: HER2

A
  • trastuzumab (breast cancer)

- lapatinib (breast cancer)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

biomarkers for selection of cancer therapy: KRAS

Study These Flashcards
A

cetuximab (colon cancer)

17
Q

oncotype DX scoring

Study These Flashcards
A
  • for breast cancer therapy with tamoxifen
  • recurrence score
  • 31 high risk (benefit from chemo)
18
Q

MammaPrint

Study These Flashcards
A
  • breast cancer therapy
  • predict risk of metastasis
  • aggressive therapy can be considered for those with poor prognosis
  • for pts <61, early stage I & II
19
Q

DPD (Dihydroprimidine dehydrogenase)

Study These Flashcards
A
  • drug disposition in cancer therapy

- DPD responsible for >85% 5-FU breakdown

20
Q

thymidylate synthase (TS)

Study These Flashcards
A
  • drug disposition in cancer therapy
  • molecular target for 5-FU
  • over expression linked to drug resistance
21
Q

PGX factors in targeted therapy

Study These Flashcards
A 
genetic variations in pathogens, targeted genes, in genes associated with drug metabolism/dispoition, & in signalling pathways involved in drug response & toxicity
other factors (interactions & physiology/disease status)
22
Q

purpose of PG testing

Study These Flashcards
A
  • provide evidence for PG variations
  • improve healthcare outcome by enhancing selection & dosing of therapy
  • provide rationale for stratification of subjects in clinical studies
  • facilitate PG research & developing novel drugs
23
Q

CYP2D6/PM

Study These Flashcards
A
  • poor response to tamoxifen
  • for postmenpausal women with breast cancer can be treated with aromatoase inhibitor
  • in pre-&perimenopausal women, no alternative therapy
  • test can be used for monitoring response & prognosis
24
Q

nocebo

Study These Flashcards
A

negative response to treatment

- can be an effect of PG testing

25
selection of target patient population: conventional approaches
- age. sex, race, etc - disease status, pathology, stage - co-morbidity - physiology/ pathology,: prego, liver & kidney function
26
PG approaches add on
``` PK characteristics (ADME: disease-independent)-differentiating people - PD characteristics (disease subtype)- differentiating disease ```
27
approval of race-targeted drug BiDil
- fixed dose of isosorbide dinitrate & hydralazine hcl - indication: HF; adjunct to standard therapy; black people - commercial failure; negative publicity; high cost compared to the 2 separate drugs alone - no comparison to other racial groups
28
about --- drugs prescribed to children were not tested in children; they are not labeled for pediatric use
2/3
29
policies developed to encourage testing drugs in children
- pediatric research equity act - best pharmaceuticals for children act - marking incentive: 6-month exclusivity
30
PG considerations in children
- developmental changes in gene expression in children - metabolizing enzymes-age related - pediatric diseases vs adult diseases - clinical trials in children- minimal risk - including children in clinical trials - including children in PG testing
31
lawsuit of lyme vaccine
- LYMeric - OspA triggers development of autoimmune arthritis in individuals with HLA-DR4 gene - withdrawn from market
32
OBRA90
pharmacist has to inform patient of risk of ADE if known genetic variant in patient or it will be a breach of duty
33
if PGX testing is considered different for traditional genetic testing
a detailed consent form is probably NOT needed
34
formal consent form needed if:
familial implication ancillary info needed risk of discrimination laws
35
under federal law & laws of many states
individuals DO NOT own their health data or stored specimens (at least in the sense of medical research)
36
HIPAA pricacy rule distinguishes
individually identifiable health info (IIHI) from de-identified health info
37
in general, disclosure or research use of IIHI needs
informed consent
38
de-identified health info can be used
without authorization
39
major goal of PG in clinical trials
stratify patients- improve response & reduce side effects

Pharmacogenetics (8 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions